aclacinomycin
Phase 3Small molecule
aclacinomycin is one of 74 small molecule programs targeting Acute Leukemia. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Busulfex
Akero TherapeuticsPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia2 trials
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Completed·—·Phase 1/2·NCT01690507·29 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aclacinomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShanxi Bethune Hospital